Biosimilars are a prescription for better health.
Biosimilars could lead to over $54 billion in savings over the next ten years, giving 1.2 million patients access to needed medicines.
GRx+Biosims 2020 is the premier scientific and regulatory event for the U.S. generics and biosimilars industries, featuring timely programming relevant to technical, regulatory and policy professionals.
Be a part of the only online experience for generics and biosimilars professionals.
Biosimilars: A needed alternative to costly care.
Utilization of innovative and very costly medicines is expected to grow exponentially in the coming years. With biosimilars, these advanced treatments are poised to become available at a lower cost to millions of patients in the United States. A positive regulatory environment can increase biosimilar adoption.
Browse our Resources
Hear more from experts on the potential of biosimilars and learn about Biosimilars Council efforts to increase biosimilar access for patients.
Want to keep up-to-date?
Enter your email address below and receive the Biosimilars Bulletin – our monthly newsletter with the most recent information on biosimilars in the United States.
FDA Biosimilars Approvals
Find an up-to-date list of FDA approved biosimilars and launches.
Featured Reports & Resources
These resources provide answers around what biosimilars are, why they are important, how they can improve patient access, and how they can save the United States billions of dollars.
